Mortality at maximal · people with intermediate‐stage hepatocellular carcinoma
It is very uncertain whether chemotherapy changes mortality (at maximal compared with no chemotherapy (very low certainty).
1 finding from 1 review
Short‐term and medium‐term mortality · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 5 years · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cancer‐related mortality at maximal · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review